CRTX - Cortexyme, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
41.00
+1.00 (+2.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close40.00
Open39.67
Bid0.00 x 1100
Ask0.00 x 800
Day's Range39.45 - 41.00
52 Week Range19.50 - 47.50
Volume72,694
Avg. Volume140,383
Market Cap1.1B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.33
Trade prices are not sourced from all markets
  • Cortexyme's unique approach to Alzheimer's research
    Yahoo Finance Video23 days ago

    Cortexyme's unique approach to Alzheimer's research

    Biopharmaceutical company Cortexyme is currently in a clinical trial stage, researching what they believe is a new way to treat the cause of Alzheimer's disease and other degenerative diseases. Cortexyme Co-Founder, Chairperson and CEO Casey Lynch sits down with Yahoo Finance's Adam Shapiro, Julie Hyman, and Scott Gamm to discuss.

  • Business Wire2 days ago

    Cortexyme’s Approach to Addressing a Key Underlying Cause of Alzheimer’s Detailed at Alzheimer’s Association International Conference 2019

    Cortexyme, Inc. (CRTX) today announced the presentation of clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach to treating a key underlying cause of Alzheimer’s and other degenerative diseases. In a poster presentation at the Alzheimer’s Association International Conference® 2019 (AAIC®), researchers highlighted the Phase 1b clinical development experience of COR388, the company’s lead investigational gingipain inhibitor, and provided an overview of the design for the GAIN trial, the company’s large, international Phase 2/3 trial in patients with mild to moderate Alzheimer’s disease (AD). AAIC is the largest international meeting dedicated to advancing dementia science and is being held this week in Los Angeles.

  • Business Wire9 days ago

    Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2019

    Cortexyme, Inc. (CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases will be discussed in two research abstracts at the Alzheimer’s Association International Conference® 2019 (AAIC®). The conference, which is the largest international meeting dedicated to advancing dementia science, will be held July 14-18, 2019 in Los Angeles.

  • American City Business Journals14 days ago

    These Bay Area companies are part of an uptick in women-led IPOs

    About 15 percent of the companies in the U.S. that have gone public so far in 2019 are led by female CEOs, the highest number in at last six years and triple the number of woman-run companies listed in the Russell 2000.

  • American City Business Journals18 days ago

    Here are big Bay Area winners, losers from busy first half of IPOs

    The average return on U.S. IPOs in the second quarter was 30 percent, a mark hit or exceeded by 11 of the Bay Area's 23 new public companies so far this year.

  • Business Wirelast month

    Cortexyme Expands Clinical Advisory Board With Key Clinical and Regulatory Experts

    Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced four new additions to its Clinical Advisory Board (CAB). Jeffrey Cummings, M.D., Sc.D., David Hosford M.D., Ph.D., Lon Schneider, M.D., M.S., and Pierre N. Tariot, M.D. join the CAB with deep and diverse experience in central nervous system (CNS) drug development.

  • Business Wirelast month

    Cortexyme to Present at National Academies Forum on Tuesday, June 11, 2019

    Cortexyme, Inc. (CRTX) today announced that Casey Lynch, the company’s chief executive officer, chairman, and co-founder, will present at a National Academies of Science, Engineering, and Medicine workshop on the growing understanding of the relationship between pathogens and chronic disease this week. Ms. Lynch will provide an overview of Cortexyme’s work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases during “Breaking Down Silos: The Convergence of Infectious Diseases and Noncommunicable Diseases,” which will be held June 11-12 in New York. In her remarks, Ms. Lynch will review the scientific rationale and data supporting a key role for Porphyromonas gingivalis in the development of Alzheimer’s disease, based on the identification of the bacteria in the brain of Alzheimer’s patients and its ability to cause neurodegeneration, inflammation, and other pathology associated with Alzheimer’s in animal models.

  • Business Wire2 months ago

    Cortexyme, Inc. Announces Pricing of Initial Public Offering

    Cortexyme, Inc. (CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions. In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to an additional 661,800 shares at the initial public offering price, less the underwriting discounts and commissions.

  • Benzinga2 months ago

    IPO Outlook For The Week: Uber (And 11 Others)

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...